Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. by Kano, Y. et al.
British Journal of Cancer (1996) 74, 704-710
©C) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Schedule-dependent interaction between paclitaxel and 5-fluorouracil in
human carcinoma cell lines in vitro
Y Kano" 3, M Akutsul, S Tsunoda', J Ando2, J Matsui2, K Suzuki3, T Ikeda4, Y Inoue' and
KI Adachi6
Divisions of'Medical Oncology, 2Surgery and 3Laboratory Medicine, Tochigi Cancer Center, Yonan 4-9-13, Utsunomiya, Tochigi,
320, Japan; Departments of4Surgery and 'Plastic Surgery, School ofMedicine, Keio University, Shinano-machi 35, Shinjuku-Ku,
Tokyo, 160, Japan. 6Medical Data Center, Pharmaceuticals Group, Nippon Kayaku Co., Ltd. 31-12, Shimo 3, Kita-ku, Tokyo, 115,
Japan.
Summary We assessed the cytotoxic interaction between paclitaxel and 5-fluorouracil administered at various
schedules against four human carcinoma cell lines, A549, MCF7, PAI and WiDr. The cells were exposed
simultaneously to paclitaxel and to 5-fluorouracil for 24 h or sequentially to one drug for 24 h followed by the
other for 24 h, after which they were incubated in drug-free medium for 4 and 3 days respectively. In another
experiment, the cells were exposed simultaneously to both agents for 5 days. Cell growth inhibition was
determined by MTT reduction assay. The effects of drug combinations at IC80 were analysed by the
isobologram. The cytotoxic interaction of paclitaxel and 5-fluorouracil was definitely schedule dependent.
Simultaneous exposure to paclitaxel and 5-fluorouracil for 24 h showed mainly subadditive effects in A549,
MCF7 and WiDr cell lines, whereas it showed additive effects in PAI cells. Sequential exposure to paclitaxel
followed by 5-fluorouracil showed additive effects in all cell lines. Sequential exposure to 5-fluorouracil
followed by paclitaxel showed subadditive effects in A549, MCF7 and PAl cells. Whereas it showed additive
effects in WiDr cells. These findings suggest that maximum cytotoxic effects can be obtained when paclitaxel
precedes 5-fluorouracil. Interestingly, the continuous (5-day) exposure to paclitaxel and 5-fluorouracil had
additive effects in A549, PAl and WiDr cells, indicating that the prolonged simultaneous administration of
these agents may circumvent the antagonistic interaction produced by short-term simultaneous administration.
These findings may be useful in clinical trials of combination chemotherapy with paclitaxel and 5-fluorouracil.
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Paclitaxel (taxol), a plant product isolated from the bark of
the Pacific yew, Taxus brevifolia (Wani et al., 1971), is a novel
antimicrotubular agent that binds to the microtubules,
promotes microtubule assembly and stabilises tubulin
polymer formation (Schiff et al., 1979, 1981; Kumar et al.,
1981). In clinical studies, the dose-limiting toxicity of
paclitaxel was shown to be granulocytopenia; other toxic
effects shown were hypersensitivity reaction, neuropathy,
mucositis, slight nausea and vomiting, and slight cardiac
injury (Grem et al., 1987; Donehower et al., 1987; Wiernilk et
al., 1987). Significant paclitaxel anti-tumour activity has been
reported in patients with ovarian, breast, lung, head and
neck, and oesophageal cancers (McGuire et al., 1989; Holms
et al., 1991; Donehower et al., 1993; Ettinger et al., 1993;
Murphy et al., 1993). Its impressive clinical activity has
prompted considerable interest in combining this drug with
other anti-tumour agents. Clinical trials of its anti-tumour
effects in combination with several other anti-tumour agents
are now in progress.
For many years, 5-fluorouracil has been the mainstay of
therapy for patients with solid tumours. 5-Fluorouracil, alone
or in combination with other agents, is widely used in the
treatment of gastrointestinal, breast and lung cancers-all
non-curable diseases. It would be attractive to use paclitaxel
and 5-fluorouracil in combination against these malignancies.
As paclitaxel exerts its cytotoxic effects through a mechanism
different from that of 5-fluorouracil, and it has no cross-
resistance with 5-fluorouracil (Gupta, 1983), it appears
reasonable to attempt to use these drugs in combination.
Clinical trials of the combination of paclitaxel and 5-
fluorouracil in a variety of schedules have, indeed, been
initiated (Elkordy et al., 1994; Klaassen et al., 1994;
Madajewicz et al., 1995; Paul et al., 1995; Takimoto et al.,
1995). However, it has not been determined whether
paclitaxel and 5-fluorouracil should be given concomitantly
or sequentially, or what the optimal infusion durations of
each drug are. It is important to identify the optimal schedule
for this combination; hence, in the present study, we
attempted to elucidate the cytotoxic effects of paclitaxel and
5-fluorouracil combinations administered at various schedules
in four human carcinoma cell lines.
Materials and methods
Cell lines
Experiments were conducted with four human carcinoma cell
lines; non-small-cell lung cancer cells, A549, breast cancer
cells, MCF7, ovarian cancer cells, PAl and the colon cancer
cells, WiDr. These cells were obtained from the American
Type Culture Collection (Rockville, MD, USA) and
maintained in 75 cm3 plastic tissue culture flasks containing
RPMI-1640 medium (Grand Island Biological Co., Grand
Island, NY, USA) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Grand Island Biological Co.) and
antibiotics. The doubling times of A549, MCF7, PAl and
WiDr cells in our experimental conditions were 30, 27, 24 and
27 h respectively.
Drugs
Paclitaxel and 5-fluorouracil were provided by Bristol Myers
Squibb Japan (Tokyo), and Kyowa Hakko (Tokyo)
respectively. Paclitaxel was dissolved in dimethyl sulphoxide
(Sigma, St Louis, MO, USA) and 5-fluorouracil was
dissolved in RPMI-1640. The drugs were diluted with
RPMI-1640 plus 10% FBS. The final concentration of
dimethyl sulphoxide in the media was less than 0.05% and
it had no effect on cell growth inhibition.
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Exponentially growing cells were harvested with trypsin
(0.05%)/EDTA (0.02%) and resuspended, to a final
concentration of 5.0 x I03 cells ml-, in fresh medium
containing 10% FBS and antibiotics. Aliquots of cell
suspensions (100 ,l) were dispensed with a multichannel
pipette into the individual wells of a 96-well tissue culture
plate with lid (Falcon, Oxnard, CA, USA). Each plate had
one eight-well control column containing medium alone and
one eight-well control column containing cells but no drug.
Four plates were prepared for each drug combination
schedule in each cell line. The cells were reincubated
overnight in a humidified atmosphere containing 5% carbon
dioxide at 37°C to allow for attachment.
Simultaneousexposure (24 h) topaclitaxeland5-fluorouracil -
After 20 to 24 h incubation, aliquots (50 ,l) of each drug
solution, at different concentrations, were added to individual
wells (paclitaxel preceding 5-fluorouracil by approximately
10 min). The plates were then incubated under the same
conditions for 24 h. After treatment, the cells were washed
once with culture medium containing 1% FBS, and fresh
medium (200 ll) was provided. The cells were then incubated
again for 4 days.
Sequential exposure to paclitaxel and 5-fluorouracil After 20
to 24 h incubation, aliquots of media containing 10% FBS
(50 ,l) and solutions of paclitaxel (or 5-fluorouracil) (50 PIl)
at different concentrations were added to individual wells.
The plates were then incubated under the same conditions for
24 h. The cells were washed once with culture medium
containing 1% FBS and fresh medium containing 10% FBS
(150 ,ul) and antibiotics, and aliquots of 5-fluorouracil (or
paclitaxel) solution (50 pl) at different concentrations were
added. The plates were incubated again under the same
conditions for 24 h. After treatment, the cells were washed
once, and fresh medium (200 Al) was provided. The cells were
then incubated again for 3 days.
Continuous and simultaneous exposure to paclitaxel and 5-
fluorouracil After 20 to 24 h incubation, aliquots of
paclitaxel (50 jMl) and 5-fluorouracil (50 pl) solution at
different concentrations were added to individual wells. The
plates were then incubated under the same conditions for 5
days.
MTT assay
Viable cell growth was determined by MTT reduction assay
(Mosmann, 1983) as described previously (Kano et al., 1991).
Aliquots of 50 ul of MTT (1 mg ml-') were added to each
well. After 4 h at 37°C, the supernatant was removed.
Dimethyl sulphoxide (150 ,l) was then added and the plates
were vigorously shaken to solubilise the MTT-formazan
product. Absorbance at 570 nm was measured with a Titertek
multiscan. For all cell lines studied, we established a linear
relation between the MTT assay and cell number within the
range of the experiments shown.
Data analysis
Dose-response curves were plotted on a semilog scale as a
percentage of the control, the cell number of which was
obtained from samples with no drug exposure that were
processed simultaneously. Dose-response interactions be-
tween paclitaxel and 5-fluorouracil at the point of IC80 were
evaluated by the isobologram (Steel and Peckham, 1979). The
IC80 was defined as the concentration of drug that produced
80% cell growth inhibition; 80% reduction ofabsorbance. We
used IC80 instead of the more common IC50 as the combined
effects at IC50 were sometimes different from those of IC80,
which would be more important than ICso in this study.
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Figure 1 shows a schematic isobologram. The theoretical
basis of the isobologram has been described previously (Steel
and Peckham, 1979; Kano et al., 1988, 1992). Three isoeffect
curves were constructed based upon the dose-response
curves of paclitaxel and 5-fluorouracil.
(1) Mode I line (solid line in Figure 1): When the dose of
paclitaxel was chosen, an incremental effect remained to be
produced by 5-fluorouracil. The addition was calculated by
takingthe increment indoses, startingfromzero, thatproduced
log survivals that added up to IC80 (heteroaddition). If the
agents are acting additively by independent mechanism,
combined data points would lie near the mode I line.
(2) Mode 11 (a) line (dotted line in Figure 1). When the
dose of paclitaxel was chosen, an incremental effect remained
to be produced by 5-fluorouracil. The addition was calculated
by taking the increment in doses, starting from the point on
the dose-response curve of paclitaxel where the effect of
paclitaxel had ended, that produced log survivals that added
up to IC80 (isoaddition).
(3) Mode 11 (b) line (dotted line in Figure 1). Similarly to
procedure for the mode II (a) line, when the dose of 5-
fluorouracil was chosen, an incremental effect remained to be
produced by paclitaxel. The addition was calculated by taking
the increment in doses, starting from the point on the dose-
response curve of5-fluorouracil where its effect hadended, that
produced log survivals that added up to IC80 (isoaddition). If
the agents are acting additively by similar mechanism,
combined data points would lie near mode II lines.
As we cannot know whether the combined effects of two
agents will be heteroadditive, isoadditive or intermediate
between these extremes, all possibilities should be considered.
Thus, when the data points ofthe drug combination fell within
the area surrounded by three lines (envelope ofadditivity) (Pb
in Figure 1), the combination was regarded as additive. We
used this envelope not only to evaluate simultaneous exposure
to the paclitaxel and 5-fluorouracil combination, but also to
evaluate the sequential exposure to both agents as the
cytotoxicity of the first agent could be modulated by the
second agent under our experimental conditions.
In this isobologram, an additive effect indicates great
superiority of the combination to a single agent, even
though the data points for the combination do not reach
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Figure 1 Schematic representation of isobologram. Envelope of
additivity 1, surrounded by mode I (solid line) and mode II
(dotted lines) isobologram lines, was constructed from the dose-
response curves of paclitaxel and 5-fluorouracil (5-FU). The
concentrations that produced 80% cell growth inhibition were
expressed as 1.0 in the ordinate and the abscissa of isobolograms.
Combined data points Pa, Pb, Pc, and Pd show supra-additive,
additive, subadditive and protective effects respectively.
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a the supra-additive area. Thus, anti-cancer agents that show 100 additive etects should have greater cytotoxic effects in
5,FU (gm) combinations than when used as single agents. When the data 5EU (JiM) points fell to the left of the envelope (i.e. the effect of the
o 0 combination was caused by lower doses ofthe two agents than
* 1 predicted) (Pa in Figure 1), we regarded the drugs as having a
o \ * 2 supra-additive effect (synergism). When the points fell to the : 50A right of the envelope (i.e. the effect of the combination was
A 5 caused by higher doses of the two agents than predicted), but
a) \ 10 within the square or on the line ofthe square (Pc in Figure 1), O \ \\ * 20 we regarded the two drugs as having a subadditive effect, that
is, the combination was superior or equal to a single agent but
was less than additive. When the data points were outside the
Q0 \ \\\square (Pd in Figure 1), the combination was regarded as E . X \\ \ having a protective effect, i.e. the combination was inferior in C ) \ cytotoxic action to a single agent. Both subadditive and
oD protective interaction were regarded as antagonism.
Results
0 1 2 3 4 5 6 Figure 2a-c shows dose-response curves for MCF7 cells
exposed to paclitaxel and 5-fluorouracil for 24 h at various
100 schedules; simultaneous exposure to drugs, sequential
exposure to paclitaxel followed by 5-fluorouracil and
I s sequential exposure to 5-fluorouracil followed by paclitaxel
respectively. Paclitaxel concentrations are shown on the
abscissa. Dose-response curves, in which 5-fluorouracil
o \ \\ concentrations are shown on the abscissa, can be made : 50 - based on the same data (figure not shown). Isobolograms at
0
2 > G \\ the IC80 level were generated using these dose -response
curves for the combinations.
CL I \ \\Simultaneous exposure (24 h) to paclitaxel and 5-fluorouracil
.0 \ \tFigure 3a-d shows isobolograms of A549, MCF7, PAl and
\ WiDr cells respectively, simultaneously exposed to paclitaxel
and 5-fluorouracil. In A549, MCF7 and WiDr cells, the data
points for the combination fell mainly in the area of
subadditivity; these findings we regarded as indicative of
simultaneous exposure produced slight antagonistic effects. In
PAl cells, the data points for the combination fell within the
10 1 2 envelope of additivity, suggesting that the combination had o 1 2 3 4 5 additive effects.
C
100
Sequential exposure to paclitaxelfollowed by 5-fluorouracil
Figure 4a-d shows isobolograms of A549, MCF7, PAl and
WiDr cells respectively. In this experimental condition, all cell
lines showed similar effects; most of the data points for the
50 At combination fell within the envelope of additivity, suggesting
o 50 that sequential exposure to paclitaxel followed by 5- fluorouracil produced additive effects.
Sequential exposure to 5-fluorouracilfollowed by paclitaxel 0.
Figure 5a-d shows isobolograms of A549, MCF7, PAl and .0 WiDr cells respectively. In A549, MCF7 and PAl cells, the
E
_ data points for the combination fell mainly in the area of
subadditivity and protection, suggesting antagonistic effects
in this condition. In WiDr cells, the data points for the
combination fell within the envelope of additivity, suggesting
additive effects.
10
o 1 2 3 4 5
Paclitaxel (nM)
Figure 2 Dose-response curves for paclitaxel alone, 5-fluorour-
acil (5-FU) alone, and their combinations in MCF7 cells. (a) exposed to drugs). Paclitaxel concentrations are shown on the
Simultaneous exposure (24h) to paclitaxel and 5-fluorouracil. (b) abscissa. 5-Fluorouracil concentrations for each symbol are in the
Sequential exposure to pacitaxel (24h) followed by 5-fluorouracil upper right ofpanel (a). Each point represents the mean value for
(24h). (c) Sequential exposure to 5-fluorouracil (24h) followed by at least three independent experiments performed in quadrupli-
paclitaxel (24h). Cell numbers were measured by MTT assay after cate; the s.e. of the means were less than 11% and were then
5 days and were plotted as a percentage of the control (cells not omitted.Paclitaxel and 5-fluorouracil combination
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Figure 3 Isobolograms of simultaneous exposure to paclitaxel and 5-fluorouracil (5-FU) in A549, MCF7, PAl and WiDr cells.
Data are presented as mean values+s.e. (bars) for at least three independent experiments (some data points have error bars that are
concealed by the symbol). In A549, MCF7 and WiDr cells, the data points of the combinations fell mainly in the area of
subadditivity, suggesting that the combination showed slight antagonistic effects. In PA-1 cells, the data points fell within the
envelope of additivity, suggesting additive effects.
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Continuous simultaneous exposure to paclitaxel and 5-
fluorouracil
Figure 6a-d shows isobolograms of A549, MCF7, PAl and
WiDr cells respectively. In A549, PAl and WiDr cells, most
data for the combination fell within the envelope of
additivity, suggesting additive effects in this condition. In
MCF7, the data points for the combination fell within the
envelope of additivity and in the area of subadditivity,
suggesting slight antagonistic effects.
Discussion
Paclitaxel is an important new drug with a novel mechanism
of action and broad clinical activity. The optimal dose and
schedule of paclitaxel, either as a single agent or in
combination with other anti-cancer agents, has not yet been
established (Arbuck, 1994). The purpose of this study was to
assess the cytotoxic interaction between paclitaxel and 5-
fluorouracil, administered at various schedules, against four
human cancer cell lines. The cytotoxic effect of the
combination at IC80 was analysed by the isobologram
method (Steel and Peckham, 1979).
Our studies clearly demonstrated that the cytotoxic
interaction between paclitaxel and 5-fluorouracil was schedule
dependent. Simultaneous exposure to these two agents for 24 h
had slight antagonistic effects in three of the four human
carcinoma cell lines examined. Sequential exposure to 5-
fluorouracil for 24 h followed by paclitaxel for 24 h had
antagonistic effects in all four cell lines, whereas sequential
exposure to paclitaxel for 24 h followed by 5-fluorouracil for
24 h had additive effects in three ofthe four cell lines.
As combination schedules with antagonistic interaction are
not generally employed, the short-term simultaneous admin-
istration of these two agents and the sequential administra-
1.2 A54
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X0.6
Paclitaxel
U-
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tion of 5-fluorouracil followed by paclitaxel may be
inappropriate in clinical use. In particular, the sequential
administration of 5-fluorouracil followed by paclitaxel is not
recommended as this sequence had mainly protective effects,
suggesting that this combination would be no more effective
than either single drug alone.
The mechanisms of antagonistic interaction operating with
these schedules are obscure. As cells are most sensitive
against paclitaxel in M-phase (Lopes et al., 1993), it is likely
that 5-fluorouracil, which blocks cells in S-phase and prevents
cells from entering M-phase, would be antagonistic with
paclitaxel if both agents were exposed simultaneously or 5-
fluorouracil precedes paclitaxel exposure. However, when
cells are exposed to paclitaxel first, cells are blocked in G2/M.
Paclitaxel is considered to reduce cytotoxicity due to 5-
fluorouracil by preventing cells entering S-phase, in which
cells are most sensitive to 5-fluorouracil. The latter
speculation is not always consistent with our findings that
sequential exposure to pacitaxel followed by 5-fluorouracil
showed additive effects. The changes in the cell cycle
transition may be insufficient to explain cytotoxic interaction
between these agents. The study of 5-fluorouracil-induced
alterations in cell cycle kinetics, uptake, and biochemical
pharmacology ofpaclitaxel or vice versa, will be important to
clarify the mechanism of additive or antagonistic interaction
between two agents in various schedules.
Our findings suggest that the sequential administration of
pacitaxel followed by 5-fluorouracil may be a suitable
schedule in terms of cytotoxic effects. However, as paclitaxel
and 5-fluorouracil exhibit a dose-limiting toxicity of
granulocytopenia, the combination of these two agents may
raise the usual oncological problem of the concomitant
increase of both efficacy and myelotoxicity. The use of
granulocyte colony-stimulating factor could eliminate the
granulocytopenia, and, thus, prevent a reduction in the dose
level of this combination.
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Figure 5 Isobolograms of sequential exposure to 5-fluorouracil (5-FU) followed by paclitaxel in A549, MCF7, PAI and WiDr
cells. Data are presented as mean values+s.e. (bars) for at least three independent experiments (some data points have error bars
that are concealed by the symbol). In A549, MCF7 and PAl cells, the data points for the combination fell in the area of
subadditivity and protection, suggesting antagonistic effects. In WiDr cells, the data points for the combination fell within the
envelope of additivity, suggesting additive effects.
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Although paclitaxel has been administered as 3 h and 24 h
infusions (Arbuck, 1994), its optimal schedule as a single
agent has not yet been determined. In human cancer cell lines
in culture, the cytotoxic effects of paclitaxel seemed to
increase more with prolongation of exposure time than with
increases in the concentration (Rowinsky et al., 1988; Lopes
et al., 1993). Longer drug exposure times partially overcome
multidrug resistance, a mechanism that operates in a variety
of cancers (Lai et al., 1991). Some recent clinical trials of
paclitaxel have shown that prolonged infusion schedules may
be more effective than shorter schedules (Wilson et al., 1994).
5-Fluorouracil has been administered by bolus infusion and
by continuous long-term infusion. This drug exhibits different
modes of action, depending on the administration schedule,
the major mechanism of action of 5-fluorouracil in short-term
exposure being considered to be the incorporation of
fluorouridine triphosphate into RNA, and that operating in
long-term exposure, the inhibition of thymidylate synthase by
5-fluoro-2'-deoxyuridylate (Aschele et al., 1992). These
findings suggest that the effects of simultaneous exposure to
the combination of paclitaxel and 5-fluorouracil may vary
depending on exposure time.
We, therefore, also studied the effects of the combination
of these two agents in cells exposed simultaneously to both
agents for 5 days. Interestingly, the simultaneous exposure
to paclitaxel and 5-fluorouracil had additive effects in three
of the four cell lines, although simultaneous exposure to
these two agents for 24 h had antagonistic effects in three
of the four cell lines. We also observed that simultaneous
exposure to these two agents for 4 h had antagonistic
effects in all cell lines (data not shown). These findings
suggest that the prolonged simultaneous administration of
paclitaxel and 5-fluorouracil may circumvent the antagonis-
tic interaction seen with short-term simultaneous adminis-
tration.
The pharmacokinetic interactions of paclitaxel and
cisplatin and paclitaxel and doxorubicin have recently been
studied (Rowinsky et al., 1991; Holmes et al., 1994).
Interestingly, the sequential administration of cisplatin
followed by paclitaxel decreased paclitaxel clearance, result-
ing in higher toxicity than the reverse sequence. With the
paclitaxel and doxorubicin combination, the sequential
administration of paclitaxel followed by doxorubicin
decreased doxorubicin clearance, resulting in higher toxicity
than the reverse sequence. Clinical studies of the pharmaco-
kinetic interactions and toxicities of paclitaxel administered
with 5-fluorouracil may also be important in designing
clinical regimens.
In conclusion, the present study showed that simultaneous
exposure to paclitaxel and 5-fluorouracil and sequential
exposure to 5-fluorouracil followed by paclitaxel had
antagonistic effects, whereas sequential exposure to paclitax-
el followed by 5-fluorouracil had additive effects. These
findings suggest that the sequential administration of
paclitaxel followed by 5-fluorouracil may be the optimal
schedule for this combination. Long-term exposure to both
agents had mainly additive effects, suggesting that the
prolonged simultaneous administration of both agents may
circumvent the antagonistic interaction that occurred with
short-term simultaneous administration. Further preclinical
and clinical investigations of this combination are required to
better understand its anti-tumour, toxic and pharmacokinetic
interactions.
Abbreviations
FBS, fetal bovine serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazonium bromide.
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